Tuesday, 14 February 2012

SUMMIT OUTLINES CLINICAL TRIAL PLANS FOR ITS DUCHENNE MUSCULAR DYSTROPHY PROGRAMME - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

SUMMIT OUTLINES CLINICAL TRIAL PLANS FOR ITS DUCHENNE MUSCULAR DYSTROPHY PROGRAMME
"Clinical Trial Application expected to be submitted in Q1 2012
• Headline results from Phase I study anticipated in Q3 2012
Oxford, UK, 14 February 2012, Summit (AIM: SUMM), a UK drug discovery company, today outlines
its clinical trial plans for SMT C1100, a potential first-in-class disease modifying drug for the treatment
of the fatal rare disease Duchenne Muscular Dystrophy (‘DMD’). "

'via Blog this'

No comments:

Post a comment